EUVIMEDEUVIMED entdecken
Open Access

Crohn’s Patient Serum Proteomics Reveals Response Signature for Infliximab but not Vedolizumab

Carlos G Gonzalez iD, Toer W Stevens, Bram Verstockt iD, David J Gonzalez, Geert D'Haens iD, Parambir S Dulai iD

Inflammatory Bowel Diseases · 03.09.2024 · 30 (9) · 1536-1545

DOI: 10.1093/ibd/izae016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 17.02.2024. Verfasst von Carlos G Gonzalez und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, University of California San Diego, La Jolla, CA, USA. Hauptthemen laut MEDLINE: Infliximab, Crohn Disease, Antibodies, Monoclonal, Humanized, Proteomics. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIH/NIDDK, Institutional Research and Career Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Crohn’s disease is a chronic inflammatory bowel disease that affects the gastrointestinal tract. Common biologic families used to treat Crohn’s are tumor necrosis factor (TNF)-α blockers (infliximab and adalimumab) and immune cell adhesion blockers (vedolizumab). Given their differing mechanisms of action, the ability to monitor response and predict treatment efficacy via easy-to-obtain blood draws remains an unmet need.

Methods

To investigate these gaps in knowledge, we leveraged 2 prospective cohorts (LOVE-CD, TAILORIX) and profiled their serum using high-dimensional isobaric-labeled proteomics before treatment and 6 weeks after treatment initiation with either vedolizumab or infliximab.

Results

The proportion of patients endoscopically responding to treatment was comparable among infliximab and vedolizumab cohorts; however, the impact of vedolizumab on patient sera was negligible. In contrast, infliximab treatment induced a robust response including increased blood-gas regulatory response proteins, and concomitant decreases in inflammation-related proteins. Further analysis comparing infliximab responders and nonresponders revealed a lingering innate immune enrichments in nonresponders and a unique protease regulation signature related to clotting cascades in responders. Lastly, using samples prior to infliximab treatment, we highlight serum protein biomarkers that potentially predict a positive response to infliximab treatment.

Conclusions

These results will positively impact the determination of appropriate patient treatment and inform the selection of clinical trial outcome metrics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InfliximabCrohn DiseaseAntibodies, Monoclonal, HumanizedProteomicsGastrointestinal AgentsHumansFemaleAdultMaleProspective StudiesMiddle AgedTreatment OutcomeBiomarkersYoung Adult

Stichwörter der Autor:innen

Crohn’s diseaseinfliximabproteomicsserumvedolizumab

Substanzen

InfliximabvedolizumabAntibodies, Monoclonal, HumanizedGastrointestinal AgentsBiomarkers

Autor:innen und Institutionen

  • Department of Pharmacology, University of California San Diego, La Jolla, CA, USA.
  • Skaggs School of Pharmacy, University of California San Diego, La Jolla, CA, USA.
  • Department of Pediatrics, University of California San Diego, La Jolla, CA, USA.
  • Department of Gastroenterology and Hepatology, Amsterdam University Medical Centers, Amsterdam, the Netherlands.
  • Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
  • Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.

ORCID-Profile: Carlos G Gonzalez, Bram Verstockt, Geert D'Haens, Parambir S Dulai

Förderung

  • NIDDK NIH HHS
  • NIH/NIDDK
  • Institutional Research and Career Development
  • NIGMS NIH HHS
  • NIH/NIDDK U planning grant
  • National Institute of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • Clinical Research Fund

Zitieren

APA

Gonzalez, C. G., Stevens, T. W., Verstockt, B., Gonzalez, D. J., D'Haens, G., & Dulai, P. S. (2024). Crohn’s Patient Serum Proteomics Reveals Response Signature for Infliximab but not Vedolizumab. Inflammatory Bowel Diseases, 30(9), 1536-1545. https://doi.org/10.1093/ibd/izae016

Vancouver

Gonzalez CG, Stevens TW, Verstockt B, Gonzalez DJ, D'Haens G, Dulai PS. Crohn’s Patient Serum Proteomics Reveals Response Signature for Infliximab but not Vedolizumab. Inflammatory Bowel Diseases. 2024;30(9):1536-1545. doi:10.1093/ibd/izae016

BibTeX
@article{Gonzalez2024,
  author = {Gonzalez, Carlos G and Stevens, Toer W and Verstockt, Bram and Gonzalez, David J and D'Haens, Geert and Dulai, Parambir S},
  title = {Crohn’s Patient Serum Proteomics Reveals Response Signature for Infliximab but not Vedolizumab},
  journal = {Inflammatory Bowel Diseases},
  year = {2024},
  volume = {30},
  number = {9},
  pages = {1536--1545},
  doi = {10.1093/ibd/izae016}
}
Kostenlos starten →